court Judge David R. Herndon has announced that the first trial in MDL 2100 – “Yasmin and Yaz (drospirenone) Marketing, Sales Practices and Products Liability Litigation”- has moved to January 2012. This announcement came in May 2011, that trial would start in January 2012. The case selected for trial is a Yaz blood clot case that resulted in pulmonary embolism case. Around 6000 cases, involving 8,000 individual plaintiffs have been transferred to Judge Herndon’s court, which was designated as the court for all such cases in the federal court system.  The vast majority of these lawsuits were against the makers of Yaz, Yasmin and Ocella, which is a generic version of Yaz, where the alleged injury is related to blood clots.

Yaz and Yasmin are oral contraceptive drugs manufactured by Bayer pharmaceuticals. Both these drugs are oral contraceptive pills. Both of them contain ethinyl estradiol (estrogen) and drospirenone. Yaz contains 3mg of drospirenone and 0.02 mg of ethinyl estradiol per tablet, whereas Yasmin contains 3 mg of drospirenone and 0.03 mg of ethinyl estradiol per tablet. Yasmin is prescribed for prevention of pregnancy only, whereas Yaz has been approved by for treatment of premenstrual dysphoric disorder and moderate acne too. Yaz and Yasmin have been linked to many severe side effects, such as blood clots, gallbladder diseases and gallstone problems, pulmonary embolism and deep vein thromboembolism (DVT).

Previous ArticleYaz-Yasmin Class Action Lawsuit Denied by Federal Judge Next ArticleYaz-Yasmin Lawsuits Consolidated in Pennsylvania, New Jersey and Illinois
Verdicts and Settlements
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers